Search

Search Results

• Guest Editor: G. Castaman GENE THERAPY FOR HEMOPHILIA: FACTS AND QUANDARIES IN THE 21ST CENTURY GENE THERAPY FOR HEMOPHILIA

  Bhavya S Doshi, Valder R Arruda, Valder R Arruda

  e2020069

  2020-09-08

  https://doi.org/10.4084/mjhid.2020.069

  2103

  PDF: 1908

  HTML: 352

• THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION

  Sumit Dahal, Smrity Upadhyay, Rashmi Banjade, Prajwal Dhakal, Navin Khanal, Vijaya Raj Bhatt

  e2017019

  2017-03-01

  https://doi.org/10.4084/mjhid.2017.019

  4155

  PDF: 1976

  HTML: 1775

• USE OF HEMATOPOIETIC GROWTH FACTOR IN THE MANAGEMENT OF HEMATOLOGICAL SIDE EFFECTS ASSOCIATED TO ANTIVIRAL TREATMENT FOR HCV HEPATITIS

  Paola Mancino, Katia Falasca, Claudio Ucciferri, Eligio Pizzigallo, Jacopo Vecchiet

  e2010003

  2010-03-26

  https://doi.org/10.4084/mjhid.2010.003

  1128

  PDF: 527

  HTML: 829

• UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)

  José Luis Piñana, Estela Giménez, Lourdes Vázquez, María Ángeles Marcos, Manuel Guerreiro, Rafael Duarte, Ariadna Pérez, Carlos de Miguel, Ildefonso Espigado, Marta González-Vicent, María Suarez-Lledó, Irene García-Cadenas, Rodrigo Martino, Angel Cedillo, Monserrat Rovira, Rafael de la Cámara, David Navarro, Carlos Solano

  e2024065

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.065

  4008

  Suppl. Files: 1143

  PDF: 1089

  Html: 181

• TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA

  Michele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, Francesca Palandri, Gianantonio Rosti

  e2014005

  2014-01-02

  https://doi.org/10.4084/mjhid.2014.005

  3378

  PDF: 1490

  HTML: 4016

• CAR-T CELL THERAPY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CAR-T CELL and B-ALL

  Ugo Testa, Prof. Sica, Dr. Pelosi, Dr. Germana Castelli, Prof. Leone

  e2024010

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.010

  4326

  PDF: 3561

  HTML: 221

• THE COURSE OF HEPATITIS C INFECTION AND RESPONSE TO ANTI-VIRAL THERAPY IN PATIENTS WITH THALASSEMIA MAJOR AND HEPATITIS C INFECTION: A LONGITUDINAL, PROSPECTIVE STUDY.

  Sanaa Kamal, Sara Abdelhakam, Dr., Dahlia Ghoraba, Mohamad Amer Mohsen, Ahmed Abdelsalam, Huda Hassan, Leila Nabeigh

  e2019060

  2019-10-30

  https://doi.org/10.4084/mjhid.2019.060

  1399

  PDF: 1051

  HTML: 211

• INFECTIOUS COMPLICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA

  AnnaMaria Nosari

  e2012070

  2012-11-05

  https://doi.org/10.4084/mjhid.2012.070

  3353

  PDF: 1369

  HTML: 2675

• THE GROWING ROLE OF THE BH3 MIMETIC DRUG VENETOCLAX IN THE THERAPY OF ACUTE MYELOID LEUKEMIA

  Elvira Pelosi, Dr. Germana Castelli, Ugo Testa

  e2022080

  2022-10-29

  https://doi.org/10.4084/MJHID.2022.080

  1530

  PDF: 1174

  HTML: 288

• THE USE OF MONOCLONAL ANTIBODIES IN THE TREATMENT OF AUTOIMMUNE COMPLICATIONS OF CHRONIC LYMPHOCYTIC LEUKEMIA

  Luca Laurenti

  e2013027

  2013-04-10

  https://doi.org/10.4084/mjhid.2013.027

  2212

  PDF: 1046

  HTML: 2725

• SECOND-GENERATION TYROSINE KINASE INHIBITORS (TKI) AS SALVAGE THERAPY FOR RESISTANT OR INTOLERANT PATIENTS TO PRIOR TKIs

  Massimo Breccia, Giuliana Alimena

  e2014003

  2014-01-02

  https://doi.org/10.4084/mjhid.2014.003

  3294

  PDF: 1229

  HTML: 3475

• FACTORS INFLUENCING ADHERENCE TO IMATINIB IN INDIAN CHRONIC MYELOID LEUKEMIA PATIENTS: A CROSS-SECTIONAL STUDY

  Jyotsna Kapoor, Narendra Agrawal, Rayaz Ahmad, Sanjeev Kumar Sharma, Anshul Gupta, Dinesh Bhurani

  e2015013

  2015-02-12

  https://doi.org/10.4084/mjhid.2015.013

  1973

  PDF: 1079

  HTML: 1795

• THE HISTORY OF DEFERIPRONE (L1) AND THE COMPLETE TREATMENT OF IRON OVERLOAD IN THALASSAEMIA The history and roles of deferiprone

  George J Kontoghiorghes, Marios Kleanthous, Christina N. Kontoghiorghe

  e2020011

  2020-01-01

  https://doi.org/10.4084/mjhid.2020.011

  2437

  PDF: 1601

  HTML: 651

• TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi

  e2023038

  2023-06-29

  https://doi.org/10.4084/MJHID.2023.038

  2171

  PDF: 1722

  HTML: 384

• TYROSINE KINASE INHIBITORS AND INTERFERON

  Maria Dimou, Panagiotis Panagiotidis

  e2014006

  2014-01-02

  https://doi.org/10.4084/mjhid.2014.006

  2891

  PDF: 1453

  HTML: 3058

  Cover Letter: 213

• THERAPY-RELATED MYELOID NEOPLASMS IN CHRONIC LYMPHOCYTIC LEUKEMIA AND WALDENSTROM MICROGLOBULINEMIA

  Francesca Ricci, Alessandra Tedeschi, Marco Montillo, Enrica Morra

  e2011031

  2011-07-08

  https://doi.org/10.4084/mjhid.2011.031

  2300

  PDF: 953

  HTML: 2382

• BCR SIGNALING INHIBITORS: AN OVERVIEW OF TOXICITIES ASSOCIATED WITH IBRUTINIB AND IDELALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

  Lorenzo Falchi, Jessica M Baron, Carrie Anne Orlikowski, Alessandra Ferrajoli

  e2016011

  2016-02-10

  https://doi.org/10.4084/mjhid.2016.011

  4360

  PDF: 1491

  HTML: 3627

• CYTOKINE RESPONSE ASSOCIATED WITH HEPATITIS C VIRUS CLEARANCE IN HIV COINFECTED PATIENTS INITIATING PEG INTERFERON-? BASED THERAPY.

  Truong Tam Nguyen, Reihani Niloofar, Pierre-Alain Rubbo, Kuster Nils, Karine Bollore, Jacques Ducos, Georges-Philippe Pageaux, Jacques Reynes, Philippe Van de Perre, Edouard Tuaillon

  e2016003

  2016-01-01

  https://doi.org/10.4084/mjhid.2016.003

  3156

  PDF: 922

  HTML: 2053

  Untitled: 180

• PROGNOSTIC SIGNIFICANCE OF TRANSCRIPT-TYPE BCR/ABL1 IN CHRONIC MYELOID LEUKEMIA

  matteo molica, elisabetta abruzzese, massimo breccia

  e2020062

  2020-09-12

  https://doi.org/10.4084/mjhid.2020.062

  3853

  PDF: 1616

  HTML: 665

• OUTCOME OF FRONTLINE TREATMENT WITH “GENERIC” IMATINIB IN ADULT PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN ALGERIAN POPULATION: A MULTICENTER STUDY

  Mohamed Amine BEKADJA

  e2017062

  2017-10-25

  https://doi.org/10.4084/mjhid.2017.062

  2879

  PDF: 741

  HTML: 912

• MANAGEMENT OF HBV INFECTION DURING IMMUNOSUPPRESIVE TREATMENT

  Alfredo Marzano

  e2009025

  https://doi.org/10.4084/mjhid.2009.025

  864

  PDF: 490

  HTML: 1308

• ANTIFUNGAL THERAPY IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS

  Alessandro Busca, Livio Pagano

  e2016039

  2016-09-01

  https://doi.org/10.4084/mjhid.2016.039

  4797

  PDF: 1571

  HTML: 2251

  Untitled: 219

  Untitled: 235

  Untitled: 239

  Untitled: 224

  Untitled: 227

• The THE PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW: PART 2-FOCUS ON THERAPY

  Michele Bibas

  e2024015

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.015

  1810

  PDF: 1691

  HTML: 894

• DRUG THERAPY IN THE PROGRESSED CML PATIENT WITH MULTI-TKI FAILURE

  Ibrahim C. Haznedaroglu

  e2015014

  2015-12-02

  https://doi.org/10.4084/mjhid.2015.014

  277698

  PDF: 1811

  HTML: 3875

• OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE

  Grzegorz Helbig, Grazyna Bober, Marek Seweryn, Ryszard Wichary, Andrzej Tukiendorf, Lech Sedlak, Tomasz Oleksy, Slawomira Kyrcz-Krzemien

  e2015003

  2015-01-01

  https://doi.org/10.4084/mjhid.2015.003

  2254

  PDF: 1059

  HTML: 1989

  Characteristic of study group: 208

• TYROSINE KINASE INHIBITORS AND PREGNANCY

  Elisabetta Abruzzese, Malgorzata Monika Trawinska, Paolo De Fabritiis, Alessio Pio Perrotti

  e2014028

  2014-04-07

  https://doi.org/10.4084/mjhid.2014.028

  3649

  PDF: 1663

  HTML: 2680

• AUTOIMMUNE CYTOPENIAS IN CHRONIC LYMPHOCYTIC LEUKEMIA, FACTS AND MYTHS

  Pavankumar Tandra, Jairam Krishnamurthy, Vijaya Bhatt, Kam Newman, James O Armitage, Mojtaba Akhtari

  e2013068

  2013-11-04

  https://doi.org/10.4084/mjhid.2013.068

  2224

  PDF: 1209

  HTML: 3875

• BRUTON’S TYROSINE KINASE (BTK) MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A CLINICAL VIEW.

  Stefano Molica

  e2025053

  2025-06-29

  https://doi.org/10.4084/MJHID.2025.053

  1630

  PDF: 934

  HTML: 138

• MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)

  Ibrahim C. Haznedaroglu

  e2014009

  2013-12-31

  https://doi.org/10.4084/mjhid.2014.009

  4030

  PDF: 1534

  HTML: 9192

  Untitled: 284

  Untitled: 192

  Untitled: 176

  Untitled: 170

  Untitled: 194

  Untitled: 348

• CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA CAR-T and CLL

  Ugo Testa, Dr. Elvira Pelosi, Dr. Germana Castelli, Dr. Alberto Fresa, Prof. Luca Laurenti

  e2024045

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.045

  3713

  PDF: 1625

  HTML: 80

• POEMS SYNDROME: AN UPDATE

  Andrea Nozza

  e2017051

  2017-09-01

  https://doi.org/10.4084/mjhid.2017.051

  3374

  PDF: 1661

  HTML: 1518

• HYDROXYCARBAMINE: FROM AN OLD DRUG USED IN MALIGNANT HEMOPATHIES TO A CURRENT STANDARD IN SICKLE CELL DISEASE

  Giovanna Cannas, Solene Poutrel, Xavier Thomas

  e2017015

  2017-02-15

  https://doi.org/10.4084/mjhid.2017.015

  3969

  PDF: 1180

  HTML: 1658

• Successful treatment with eltrombopag in avoiding splenectomy for patients with chronic refractory immune thrombocytopenia

  Alhossain A. Khalafallah, Zafreen Rahman, Kath Ogden, Terry Hannan

  e2012003

  2012-01-18

  https://doi.org/10.4084/mjhid.2012.003

  1437

  PDF: 835

  HTML: 1032

  Untitled: 190

• CURING HEMOGLOBINOPATHIES: CHALLENGES AND ADVANCES OF CONVENTIONAL AND NEW GENE THERAPY APPROACHES.

  Irene Motta, Valentina Ghiaccio, Andrea Cosentino, Laura Breda

  e2019067

  2019-10-30

  https://doi.org/10.4084/mjhid.2019.067

  2907

  PDF: 1862

  HTML: 767

• LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML

  Xavier Thomas, Marica Laurino, sandrine loron, marie-virginie larcher, gaëlle fossard, mohamed elhamri, alexandre deloire, marie balsat, fiorenza barraco, hélène labussière, sophie ducastelle, myriam renault, eric wattel, maël heiblig, gilles salles

  e2020020

  2020-04-27

  https://doi.org/10.4084/mjhid.2020.020

  1789

  PDF: 1181

  HTML: 253

• PATIENTS WITH HAEMOGLOBINOPATHIES AND CHRONIC HEPATITIS C: A REALLY DIFFICULT TO TREAT POPULATION IN 2016?

  Kalliopi Zachou, Pinelopi Arvaniti, Nikolaos K. Gatselis, Kalliopi Azariadis, Georgia Papadamou, Eirini Rigopoulou, George N. Dalekos

  e2017003

  2017-01-01

  https://doi.org/10.4084/mjhid.2017.003

  2958

  PDF: 989

  HTML: 2066

  Cover letter: 184

• HIV INFECTION, ANTIRETROVIRAL THERAPY AND CARDIOVASCULAR RISK

  Katleen de Gaetano Donati, Roberto Cauda, Licia Iacoviello

  e2010034

  2010-11-10

  https://doi.org/10.4084/mjhid.2010.034

  1883

  PDF: 806

  HTML: 3608

• HIV-ASSOCIATED VENOUS THROMBOEMBOLISM

  Michele Bibas, Gianluigi Biava, Andrea Antinori

  e2011030

  2011-07-08

  https://doi.org/10.4084/mjhid.2011.030

  3947

  PDF: 1495

  HTML: 8520

• CMV IN HEMATOPOIETIC STEM CELL TRANSPLANTATION

  Rafael de la Camara

  e2016031

  2016-06-20

  https://doi.org/10.4084/mjhid.2016.031

  4839

  PDF: 1797

  HTML: 2723

  Untitled: 227

• RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: CHEMOIMMUNOTHERAPY, TREATMENT UNTIL PROGRESSION WITH MECHANISM-DRIVEN AGENTS OR FINITE-DURATION THERAPY?

  Antonio Cuneo, Robin Foà

  e2019024

  2019-02-27

  https://doi.org/10.4084/mjhid.2019.024

  2725

  PDF: 1667

  HTML: 264

• BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA BLINATUMOMAB and ALL

  Ugo Testa, Elvira Pelosi, Germana Castelli, Patrizia Chiusolo

  e2024070

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.070

  1657

  PDF: 1105

  HTML: 127

• INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH CHRONIC LYMPHOPROLIFERATIVE DISORDERS IN THE ERA OF TARGET DRUGS

  Livio Pagano, Davide Facchinelli, Dr.

  e2018063

  2018-10-27

  https://doi.org/10.4084/mjhid.2018.063

  2077

  PDF: 1125

  HTML: 228

• PREVENTION AND TREATMENT OF HEPATITIS VIRUS INFECTION IN HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS

  Suparno Chakrabarti, Somnath Mukherjee

  e2009017

  2009-12-10

  https://doi.org/10.4084/mjhid.2009.017

  843

  PDF: 562

  HTML: 2461

• CONCISE REVIEW ON THE FREQUENCY, MAJOR RISK FACTORS AND SURVEILLANCE OF HEPATOCELLULAR CARCINOMA (HCC) IN ?-THALASSEMIAS: PAST, PRESENT AND FUTURE PERSPECTIVES Thalassaemia transfusion dependent, Hepatitis C, hepatocarcinoma.

  Vincenzo De Sanctis

  e2020006

  2020-01-01

  https://doi.org/10.4084/mjhid.2020.006

  4306

  PDF: 1534

  HTML: 460

• How I treat acute and persistent sickle cell pain

  Samir Ballas

  e2020064

  2020-09-08

  https://doi.org/10.4084/mjhid.2020.064

  1975

  PDF: 1125

  HTML: 491

• A CRITICAL HISTORY OF CHRONIC MYELOID LEUKEMIA

  Michele Baccarani, Fabrizio Pane

  e2014010

  2013-12-31

  https://doi.org/10.4084/mjhid.2014.010

  3270

  PDF: 1352

  HTML: 4144

• GREEK CONSENSUS ON CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATMENT

  Sotirios Sachanas, Theodoros Vassilakopoulos, Maria Angelopoulou, sotirios Papageorgiou, Emmanouil Spanoudakis, Maria Bouzani, Maria Dimou, Panagiotis Panagiotidis

  e2025014

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.014

  1400

  HTML: 159

  PDF: 879

• IRON CHELATION THERAPY IN THALASSEMIA SYNDROMES

  Paolo Cianciulli

  e2009034

  1280

  PDF: 619

  HTML: 2323

• LOW INCIDENCE RATE OF OPPORTUNISTIC AND VIRAL INFECTIONS DURING IMATINIB TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS IN EARLY AND LATE CHRONIC PHASE

  Massimo Breccia, Corrado Girmenia, Roberto Latagliata, Giuseppina Loglisci, Michelina Santopietro, Vincenzo Federico, Luigi Petrucci, Alessandra Serrao, Adriano Salaroli, Giuliana Alimena

  e2011021

  2011-05-16

  https://doi.org/10.4084/mjhid.2011.021

  1650

  PDF: 807

  HTML: 867

  jdoe, table 2 infections CML .doc: 201

  jdoe, table 1 infections CML .doc: 187

• ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN THE TREATMENT OF CHRONIC LYMPHOCITIC LEUKEMIA : WHY AND WHEN ?

  Maria L. Delioukina, Stephen J. Forman

  e2010018

  2010-06-30

  https://doi.org/10.4084/mjhid.2010.018

  1260

  PDF: 797

  HTML: 546